SEARCH:   Advanced

Blood, 15 January 2005, Vol. 105, No. 2, pp. 548-551. Prepublished online as a Blood First Edition Paper on September 14, 2004; DOI 10.1182/blood-2004-03-1000. This Article Full Text Full Text (PDF) All Versions of this Article: 2004-03-1000v1 105/2/548    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Remberger, M. Articles by Ringdén, O. Search for Related Content PubMed PubMed Citation Articles by Remberger, M. Articles by Ringdén, O. Related Collections Transplantation Brief Reports Clinical Trials and Observations Neoplasia Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Brief report Increased risk of extensive chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation using unrelated donors Mats Remberger, Dietrich W. Beelen, Axel Fauser, Nadezda Basara, Oliver Basu, and Olle Ringdén From the Centre for Allogeneic Stem Cell Transplantation and Department of Clinical Immunology, Karolinska University Hospital, Stockholm, Sweden; the Department of Bone Marrow Transplantation, University Hospital Essen, Germany; the Clinic of BMT, Haematology and Oncology, Idar-Oberstein, Germany; and the Department of Paediatric Haematology, Oncology and Endocrinology, University Hospital Essen, Germany. The long-term follow-up of a study including 214 patients receiving either peripheral blood stem cells (PBSCs) or bone marrow (BM) from an HLA-A, -B, and -DR–compatible unrelated donor is presented. Median follow-up was 4.4 (2.3-7.3) and 5.0 (0.7-8.4) years in the 2 groups, respectively. Cumulative incidence of overall chronic graft-versus-host disease (GVHD) was similar in the 2 groups (78% vs 71%), while extensive chronic GVHD was significantly more common in the PBSC group compared with the BM group (39% vs 24%, P = .03). The 5-year transplant-related mortality (TRM) was 37% in the PBSC group and 35% in the BM controls (P = .7), and overall survival was 42% in both groups. The relapse incidences were 26% and 27% in the 2 groups, respectively, resulting in a disease-free survival of 41% in both groups. In conclusion, PBSCs from HLA-compatible unrelated donors results in similar outcome compared to BM but implies an increased risk for extensive chronic GVHD. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: H. Fujii, G. Cuvelier, K. She, S. Aslanian, H. Shimizu, A. Kariminia, M. Krailo, Z. Chen, R. McMaster, A. Bergman, et al. Biomarkers in newly diagnosed pediatric-extensive chronic graft-versus-host disease: a report from the Children's Oncology Group Blood, March 15, 2008; 111(6): 3276 - 3285. [Abstract] [Full Text] [PDF] H. C. Fung, M. A. Higman, and K. van Besien Stem cell transplantation ASH Self-Assessment Program, January 1, 2007; 2007(1): 328 - 360. [Full Text] [PDF] S. J. Lee New approaches for preventing and treating chronic graft-versus-host disease Blood, June 1, 2005; 105(11): 4200 - 4206. [Abstract] [Full Text] [PDF] H. J. Deeg Optimization of Transplant Regimens for Patients with Myelodysplastic Syndrome (MDS) Hematology, January 1, 2005; 2005(1): 167 - 173. [Abstract] [Full Text] [PDF]

	Blood Online is supported in part by Genentech BioOncology and Biogen Idec
	Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020